From: The impact of Medicare prescription drug coverage on the use of antidementia drugs
Pharmacy benefit group | ||||
---|---|---|---|---|
No coverage (n = 3,939) | $150 cap (n = 2,662) | $350 cap (n = 19,014) | No cap (n = 9,487) | |
Female sex, No. (%) | 2,183 (55.42)* | 1,658 (62.28)* | 11,806 (62.09)* | 4,984 (52.54) |
Age, y, No. (%) | ||||
65-74 | 1,866 (47.37)* | 1,323 (49.70)* | 9,983 (52.50)* | 5,755 (60.66) |
75-84 | 1,746 (44.33)* | 1,080 (40.57)* | 7,478 (39.33)* | 3,232 (34.07) |
≥85 | 327 (8.30)* | 259 (9.73)* | 1,553 (8.17)* | 500 (5.27) |
Race, mean (SE) | ||||
White | 0.930 (0.002)* | 0.960 (0.001)* | 0.919 (0.001)* | 0.921 (0.001) |
African American | 0.052 (0.002)* | 0.024 (0.001)* | 0.060 (0.001)* | 0.057 (0.001) |
Status below poverty line, mean (SE) | ||||
<100% | 0.106 (0.001)* | 0.111 (0.001)* | 0.101 (0.000)* | 0.099 (0.001) |
100-200% | 0.183 (0.001)* | 0.209 (0.001)* | 0.172 (0.000)* | 0.169 (0.001) |
>200% | 0.712 (0.002)* | 0.680 (0.002)* | 0.727 (0.001)* | 0.732 (0.001) |
Urban residence, mean (SE) | 0.737 (0.005)* | 0.577 (0.007)* | 0.791 (0.002) | 0.797 (0.003) |
Income, US dollars, median (SE) | 37,573.77 (159.01)* | 34,839.85 (111.25)* | 38,957.08 (78.64)* | 39,501.05 (110.80) |
Comorbidity, No. (%) | ||||
Congestive heart failure | 507 (12.87) | 381 (14.31) | 2,656 (13.97)* | 1,240 (13.07) |
Depression | 259 (6.58)* | 215 (8.08) | 1,465 (7.71) | 725 (7.64) |
Diabetes | 905 (22.98)* | 679 (25.51) | 4,755 (25.01) | 2,464 (25.97) |
Hypertension | 2,554 (64.84)* | 1,892 (71.07) | 1,3640 (71.74)* | 6,649 (70.09) |
Ischemic heart disease | 1,110 (28.18) | 757 (28.44) | 5,551 (29.20) | 2,796 (29.47) |
Prospective risk score, mean (SE) | ||||
2004 | 0.825 (0.011) | 0.855 (0.014) | 0.859 (0.005) | 0.844 (0.008) |
2005 | 0.919 (0.012) | 0.950 (0.016) | 0.942 (0.006) | 0.924 (0.009) |
2006 | 1.034 (0.015) | 1.040 (0.017) | 1.044 (0.007) | 1.029 (0.010) |
2007 | 1.153 (0.017) | 1.186 (0.020)* | 1.176 (0.008)* | 1.141 (0.011) |
Use of medical services in 2005, mean (SE) | ||||
Outpatient visits, No. | 23.146 (0.407)* | 25.158 (0.585) | 25.134 (0.193)* | 25.876 (0.287) |
Outpatient costs, US dollars | 3,498.249 (92.900)* | 3,532.557 (124.010)* | 3,741.035 (47.238) | 3,869.198 (65.966) |
Medical costs, US dollars | 6,000.270 (186.796) | 5,837.965 (226.731) | 6,208.844 (87.559) | 6,266.855 (130.414) |
Prescriptions of antidementia drugs, mean (SE) | ||||
2004-2007 | ||||
Aricept® | 0.675 (0.064)* | 0.841 (0.090) | 0.878 (0.036) | 0.908 (0.054) |
Razadyne® | 0 | 0 | 0.008 (0.002) | 0.019 (0.005) |
Exelon® | 0.079 (0.023)* | 0.085 (0.032)* | 0.100 (0.012)* | 0.228 (0.031) |
Cognex® | 0 | 0 | 0 | 0 |
Namenda® | 0.476 (0.055) | 0.343 (0.054)* | 0.401 (0.023)* | 0.498 (0.038) |
Pre–Part D | ||||
Aricept® | 0.172 (0.026)* | 0.262 (0.039) | 0.297 (0.016) | 0.335 (0.025) |
Razadyne® | 0 | 0 | 0.008 (0.002) | 0.019 (0.005) |
Exelon® | 0.032 (0.013)* | 0.044 (0.018)* | 0.040 (0.006)* | 0.106 (0.016) |
Cognex® | 0 | 0 | 0 | 0 |
Namenda® | 0.102 (0.018) | 0.084 (0.019)* | 0.096 (0.008)* | 0.140 (0.015) |
Post–Part D | ||||
Aricept® | 0.503 (0.046) | 0.579 (0.059) | 0.581 (0.023) | 0.573 (0.033) |
Razadyne® | 0 | 0 | 0 | 0 |
Exelon® | 0.047 (0.013)* | 0.041 (0.016)* | 0.060 (0.007)* | 0.122 (0.017) |
Cognex® | 0 | 0 | 0 | 0 |
Namenda® | 0.375 (0.041) | 0.259 (0.040)* | 0.305 (0.017) | 0.357 (0.026) |